hyperin,
hyperoside,
quercetin galactoside,
quercetin-3-O-galactoside,
Hyperoside,
Hyperin,
482-36-0,
Quercetin 3-galactoside,
Hyperosid,
Quercetin-3-O-galactoside,
Hyperozide,
Jyperin,
Quercetin 3-O-beta-D-galactopyranoside,
Quercetin 3-D-galactoside,
Hyperasid,
UNII-8O1CR18L82,
Quercetin-3-galactoside,
Quercetin 3-beta-D-galactopyranoside,
quercetin galactoside,
MFCD00016933,
quercetin 3-O-galactoside,
NSC 407304,
CHEMBL251254,
CHEBI:67486,
8O1CR18L82,
QUERCETIN 3-B-D-GALACTOSIDE,
2-(3,4-Dihydroxyphenyl)-3-(beta-D-galactopyranosyloxy)-5,7-dihydroxy-4H-1-benzopyran-4-one,
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one,
4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-(.beta.-D-galactopyranosyloxy)-5,7-dihydroxy-,
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-chromen-4-one,
CCRIS 9339,
p Hyperin,
Quercetin 3-.beta.-D-galactopyranoside,
Quercetin 3-O-.beta.-D-galactopyranoside,
Hyperin,(S),
Hyperin (8CI),
AC1NQYSS,
quercetin-3-d-galactoside,
BIDD:PXR0057,
MLS000759538,
2-yloxy)-4H-chromen-4-one,
MEGxp0_000392,
SCHEMBL1250514,
ACon1_000623,
OVSQVDMCBVZWGM-DTGCRPNFSA-N,
Quercetin 3-O-beta-D-galactoside,
HMS2051H17,
quercetin 3-O--D-galactopyranoside,
ZINC3973253,
BDBM50241367,
AKOS015896780,
6-(hydroxymethyl)tetrahydro-2H-pyran-,
AN-8426,
CCG-100970,
MCULE-5363142212,
NC00220,
BC209737,
CC-29452,
CPD000466394,
S600,
SAM001246776,
SC-43872,
SMR000466394,
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-,
FT-0082599,
FT-0603413,
N1838,
A12070,
C10073,
Quercetin 3-D-galactoside, >=97.0% (HPLC),
AB00639910-03,
3-((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-,
482H360,
C-22630,
3,3',4',5,7-Pentahydroxyflavone 3-D-galactoside,
Hyperoside, primary pharmaceutical reference standard,
I07-0250,
Q-100530,
BRD-K84955386-001-01-1,
3-O-b-D-Galactopyranosyloxy-3',4',5,7-tetrahydroxyflavone,
Hyperoside, United States Pharmacopeia (USP) Reference Standard,
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl beta-D-galactopyranoside,
2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl hexopyranoside #,
4H-1-Benzopyran-4-one,2-(3,4-dihydroxyphenyl)-3-(b-D-galactopyranosyloxy)-5,7-dihydroxy-,
2-(3,4-Dihydroxy-phenyl)-5,7-dihydroxy-3-((2S,4R,5R)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-chromen-4-one,
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)-4H-chromen-4-one,
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one,
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4H-chromen-4-one,
3,3 inverted exclamation marka,4 inverted exclamation marka,5,7-Pentahydroxyflavone 3-D-galactoside,
EINECS 207-580-6,
C21H20O12,
quercetin 3-O-beta-D-glucopyranoside,
ACN-035463,
CID5281643,
C21-H20-O12,
C021304,
Hyperoside, 98%, from Abelmoschus manihot (L.) Medic. - 20MG 20mg,
2-(3,4-dihydroxyphenyl)- 3-(alpha-D-galactopyranosyloxy)-5,7-dihydroxy-4H- 1-benzopyran-4-one,
4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-(beta-D-galactopyranosyloxy)-5,7-dihydroxy-,